AR082925A1 - Parvovirus structural proteins mutated with B cell epitope cross-protective, product and related methods - Google Patents

Parvovirus structural proteins mutated with B cell epitope cross-protective, product and related methods

Info

Publication number
AR082925A1
AR082925A1 ARP110103275A AR082925A1 AR 082925 A1 AR082925 A1 AR 082925A1 AR P110103275 A ARP110103275 A AR P110103275A AR 082925 A1 AR082925 A1 AR 082925A1
Authority
AR
Argentina
Prior art keywords
aav
parvovirus
protective
virus
protein
Prior art date
Application number
Other languages
Spanish (es)
Original Assignee
Medigene Ag
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US38080910P priority Critical
Application filed by Medigene Ag, Deutsches Krebsforsch filed Critical Medigene Ag
Publication of AR082925A1 publication Critical patent/AR082925A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses
    • C12N2750/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses ssDNA Viruses
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses
    • C12N2750/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses ssDNA Viruses
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses
    • C12N2750/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses ssDNA Viruses
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Proteínas estructurales mutadas por parvovirus que comprenden inserciones de epítopos de células B de protección cruzada de una proteína L2 de VPH, estructuras multiméricas, ácidos nucleicos, células, composiciones para prevenir y/o tratar una infección con VPH y vacunas relacionadas con dichas proteínas así como a su elaboración.Reivindicación 2: La proteína estructural mutada por parvovirus de la reivindicación 10, caracterizada porque el parvovirus es derivado de virus adenoasociados (AAV), Parvovirus de ganso, Parvovirus de pato, Parvovirus de serpiente, virus de la panleucopenia felina, parvovirus canino, B19 o virus diminutos de ratón (MVM), preferiblemente a partir de un AAV seleccionado del grupo integrado por AAV bovino (b-AAV), AAV canino (CAAV), AAV1 de ratón, AAV caprino, AAV de rata, AAV aviar (AAAV), AAV1, AAV2, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, y AAV13, especialmente AAV2. Protein structural mutagenized parvovirus comprising inserts B cell epitopes cross-protective L2 protein of HPV, multimeric structures, nucleic acids, cells, compositions for preventing and / or treating infection with HPV and related vaccines such proteins as well as his elaboración.Reivindicación 2: structural protein mutated parvovirus of claim 10, wherein the parvovirus is derived from adeno-associated virus (AAV), goose parvovirus, duck parvovirus, snake parvovirus, feline panleukopenia virus, parvovirus canine, B19 or virus tiny mice (MVM), preferably from an AAV selected from the group consisting of AAV bovine (b-AAV) AAV canine (CAAV), AAV1 mouse, AAV goats, AAV rat AAV avian (AAAV), AAV1, AAV2, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13 and especially AAV2.
ARP110103275 2010-09-08 2011-09-08 Parvovirus structural proteins mutated with B cell epitope cross-protective, product and related methods AR082925A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US38080910P true 2010-09-08 2010-09-08

Publications (1)

Publication Number Publication Date
AR082925A1 true AR082925A1 (en) 2013-01-16

Family

ID=44584128

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103275 AR082925A1 (en) 2010-09-08 2011-09-08 Parvovirus structural proteins mutated with B cell epitope cross-protective, product and related methods

Country Status (2)

Country Link
AR (1) AR082925A1 (en)
WO (1) WO2012031760A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105301240A (en) * 2015-09-21 2016-02-03 山东农业大学 Duck parvovirus indirect ELISA (enzyme-linked immuno sorbent assay) detection reagent kit
WO2019043081A1 (en) * 2017-08-29 2019-03-07 Ruprecht-Karls-Universität Heidelberg Rationally designed virus-like particles for modulation of chimeric antigen receptor (car)-t-cell therapy
WO2019158636A1 (en) 2018-02-16 2019-08-22 2A Pharma Ab Parvovirus structural protein for the treatment of autoimmune diseases
EP3527223A1 (en) 2018-02-16 2019-08-21 2A Pharma AB Mutated parvovirus structural protein

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535036T3 (en) 1994-07-15 2011-07-07 Coley Pharmaceutical Group, Inc., Mass. Immunomodulative oligonucleotides
DE19905501B4 (en) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie A method of producing a recombinant adeno-associated virus, suitable compositions therefor, and use for the manufacture of a medicament
DE19925199A1 (en) 1999-06-01 2000-12-07 Medigene Ag Cytotoxic T cell epitopes of the papilloma virus L1 protein and its use in diagnosis and therapy
AT409085B (en) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh A pharmaceutical composition for immunomodulation and preparation of vaccines
DE10024334B4 (en) 2000-05-17 2006-06-01 Medigene Ag Method for introducing nucleic acid into a cell (transfection) by means of calcium phosphate
AT410173B (en) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antique composition
CA2411575C (en) 2000-06-08 2015-04-07 Walter Schmidt Immunostimulatory oligodeoxynucleotides
AU8981301A (en) 2000-08-17 2002-02-25 Cistem Biotechologies Gmbh A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (en) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vaccine composition
JP2005501004A (en) 2001-05-21 2005-01-13 インターツェル・アクチェンゲゼルシャフトIntercell Ag Nucleic acid stabilization method
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
EP2012122A1 (en) 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
EP2199301A1 (en) * 2008-12-19 2010-06-23 DKFZ Deutsches Krebsforschungszentrum Immunogenic polypeptides comprising a scaffold polypeptide and a L2 polypeptide or fragment thereof
DK2403867T3 (en) * 2009-03-04 2019-08-12 Deutsches Krebsforsch Assembly activating protein (aap) and its use for manufacturing parvovirus particles mainly consisting of vp3

Also Published As

Publication number Publication date
WO2012031760A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
Opie et al. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding
Lai et al. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors
Wu et al. Adeno-associated virus serotypes: vector toolkit for human gene therapy
Handa et al. Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors
Nam et al. Structure of adeno-associated virus serotype 8, a gene therapy vector
Kotterman et al. Engineering adeno-associated viruses for clinical gene therapy
Duan et al. Polarity influences the efficiency of recombinant adenoassociated virus infection in differentiated airway epithelia
Yang et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection
Mori et al. Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein
US7588772B2 (en) AAV capsid library and AAV capsid proteins
AU762220B2 (en) AAV5 vector and uses thereof
US10138496B2 (en) Vectors with modified initiation codon for the translation of AAV-Rep78 useful for production of AAV
EP2277996B1 (en) Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
AU780231B2 (en) Virus vectors and methods of making and administering the same
US9012224B2 (en) Chimeric vectors
CN102803478B (en) For improving one's methods of purification of Recombinant AAV carrier
Palomeque et al. Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo
Kronenberg et al. A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini
Cheung et al. Identification and molecular cloning of a novel porcine parvovirus
Boutin et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors
Yan et al. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors
Ding et al. Intracellular trafficking of adeno-associated viral vectors
Schmidt et al. Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid-and heparan sulfate proteoglycan-independent transduction activity
Louis Jeune et al. Pre-existing anti–adeno-associated virus antibodies as a challenge in AAV gene therapy
Towne et al. Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6

Legal Events

Date Code Title Description
FB Suspension of granting procedure